A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Who May Qualify: 1. Voluntarily consents to participate in this study and provides written willing to sign a consent form prior to the start of any study specific procedures. 2. ≥ 18 years of age at the time of willing to sign a consent form. 3. Diagnosis of possible, laboratory supported probable, probable, or definite ALS according to the World Federation of Neurology El Escorial. 4. Documented SOD1 mutation. 5. Forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and height (measured seated). 6. If taking riluzole or edaravone, subject must be on a stable dose or ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit. Who Should NOT Join This Trial: 1. Documented p.F21C SOD1 mutation. 2. Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed. 3. Current enrollment in any other interventional study. 4. History of or positive test result for human weakened immune system virus, hepatitis C virus antibody or hepatitis B virus. 5. Pregnant or currently breastfeeding. Always talk to your doctor about whether this trial is right for you.